The market for blood lipid-lowering drugs has sprinted by 30 billion, with statins leading the market

On September 24th, we will celebrate the 18th World Heart Day, and caring for the heart and strengthening lipid management are hot topics.
, JAMA (Journal of the American Medical Association) published TheTreatment of Cholesterol in 2017 (2017 fat-lowering treatment decision), summarizing the progress of today's research on hyperlipidemia treatment, and proposed new ideas. It is emphasized that the therapeutic goal of hyperlipidemia is not only to reduce the value of blood lipids, but also to intervene in the high-risk factors of the patients themselves through the concept of evidence-based medicine, especially to reduce the risk of middle-aged and elderly people and patients with family history of hyperlipidemia.
2016 edition of the China Adult Blood Lipid Abnormality Guidelines, china's cardiovascular events will increase by about 9.2 million from 2010 to 2030. The overall prevalence of blood lipid abnormalities in adults was as high as 40.4%. Blood lipid abnormality is a chronic disease that appears under the influence of various factors for a long time, although there are no obvious symptoms, but for the elderly, there are still 50% of arteriosclerosis, blood vessel plaques, if not strengthened management, will lead to a major disaster.statins: the main force of blood lipid-lowering drugs
There are many drugs for the treatment of hyperlipidemia, of which statins have a very good "risk-benefit ratio". In addition, the global popular variety of new blood lipid-lowering products, can not be singled out, the need for combined statins to play a synergistic therapeutic role. Research shows that statins will still dominate the first-tier market by 2025, and the world's most popular new blood lipid-lowering products are still rare in China.
with lifestyle changes and the rapid arrival of the aging process, the detection rate of cervical arterial vascular plaques is obvious. The statins represented by atvastatin have the characteristics of strong fat-lowering effect, precise efficacy, diverse function and few side effects, and now occupy an absolute advantage in the market of blood-fat-lowering drugs, which promotes the overall market growth of blood lipid-lowering drugs in China.
2016, China's market size of blood lipid-lowering drugs reached nearly 24 billion yuan, up 9.24% year-on-year, according to Milnet data. In the big health industry, it is predicted that China's blood lipid products will break through the 30 billion mark in 2019.
nearly five years, the domestic key urban public hospitals blood lipid drugs developed rapidly, the product seat constantly refreshed. The 2010 TOP5 varieties are Atovastatin, Simvastatin, Pvastatin, Aximos and Fluvastatin. By 2016, the order had changed dramatically, with top5 varieties already monopolized for statins, sorted as atovastatin, ryschuvastatin, pivastatin calcium, pvastatin, and simvastatin. Compared to 2010, the TOP5 variety market grew by 192% in 2016. The market is relentless, and only safe and effective varieties can be clinically preferred.domestic statin market: stags
In 2016, there were 84 blood lipid-lowering drug companies involved in public hospitals in key cities in China, of which statins accounted for 59%. In terms of 2016 sales, the more prominent TOP5 brands are: Dalian Pfizer's Lipto accounted for 39.63 percent, AstraZeneca's 17.19 percent, Beijing's Jialin's Ale 9.89 percent, Lu nambet's Rui will 4.76 percent, and China Resources Shuanghe's crown 4.56 percent. Atovastatin, Reshuastatin and Pivastatin have become the new big three in blood lipid reduction, accounting for 80% of China's blood lipid market.
Pfizer and AstraZeneta's statins in the U.S. and AstraZeneta have maintained high growth rates and upward trends in their top five products. Beijing Jialin Pharmaceuticals, a domestic company, has formed a strong footing in the statin market with Pfizer of the United States and AstraZeneta of the United Kingdom, thanks to the academic promotion of Atovastatin brand Ale. Although the patent expires, but because of its good cholesterol-lowering effect, high safety, cost-effective advantages, and long-term occupation of the blood lipid-lowering drug market, it is not expected to break its monopoly pattern in the next 10 years.: Good results, high safety, leading market
According to Minenet data, China's blood lipid market leader brand Atovastatin showed a rapid growth trend. In 2016, the sales of Atovastatin in domestic urban public hospitals amounted to 6,075 million yuan, the domestic retail pharmacy Atovastatin market reached 2,431 million yuan, and the two major mainstream terminals reached 8,506 million yuan.
Atovastatin brand drug Liputo, Ale listed in China for 18 years, with its good efficacy, small side effects, high safety advantages, won the trust of the vast number of doctors and middle-aged and elderly drug users, has been the first brand of cholesterol-lowering drugs.Ruishuvastatin: Small dose favorite
Ruishuvastatin was developed by Japan's Yanoyi, approved by the FDA in 2003 and developed global markets with AstraZeneta. Reshvastatin is a better hydrophedrelative drug that enters less other tissues outside the liver, and is shown to be more selective.
2007, China's CFDA approved AstraZeneta's Reshvastatin registration, the name of the product can be determined. In the following years, six domestic Rishuvastatin preparations were also on the market. At present, rishuvastatin has become the second-highst drug in the cholesterol-lowering market.
2016, sales of Rishuvastatin at public hospitals in key cities in China reached 646 million yuan, up 10.91 percent year-on-year, according to Milnet data. Of these, AstraZeneta has a fixed share of 69.81 per cent. In addition, in the past two years, Lunanbet's Ruishuvastatin by virtue of the advantages of multi-dosage form, its brand drug Rui will grow rapidly, the proportion also reached 14.01 percent, followed by Zhejiang Jingsino 7.86 percent, Zhengtian Qing's Toto 6.11 percent. It is expected that 2017 will be a domestic match-up for the import of Rishuvastatin.
Pyvastatin: Growth rate of up to 50.08%
Pyvastatin was successfully developed by Xing and First Third Co., D.Y., and was registered in Japan in November 1999 and approved by the FDA in 2008 under the name Liqing. Pivastatin dose is small, side effects are small, in 2009 by the first three total registered in the country. China Resources Shuanghe's first generic drug, Crown Shuang, entered the market in 2010 and has been gaining momentum in recent years, doubling sales in key city hospitals almost every year.
2016, sales of pivastatin in public hospitals in key cities in China reached 146 million yuan, up 50.08 percent year-on-year, according to Milnet data. Pivastatin is the smallest dose of statins, compared with similar drugs, it has better pharmacodynamic behavior, which has attracted the attention of scholars at home and abroad.
In 2016, Key City Hospital China Resources Double Crane Crown Shuang occupied 81.78 percent of the market share of pivastatin, Japan's Xinghe Liqing accounted for 13.94 percent, Jiangsu Wanbang accounted for 3.89 percent, Shandong Qidu Pharmaceuticals accounted for 0.22 percent, Zhejiang Jingxin Jingke new accounted for 0.16 percent, the overall domestic market has exceeded 800 million yuan. conclusion
bioengineering PCSK9 inhibitors are the world's most popular varieties, is a new generation of cholesterol-lowering drugs. The biggest drag on PCSK9 inhibitors in the market development process is the high price, so access to the civilian market is not easy under the trend of health care control fees. On the other hand, PCSK9 inhibitors are injectable drugs, far from oral drugs convenient and high safety, cholesterol-lowering market to promote the new still have a long way to go! (Minnet Original)